UCB SA (UCBJY)
OTHER OTC:UCBJY
UCBJY Stock Chart & Stats
$158.79
$1.86(1.89%)
At close: 4:00 PM EST
$158.79
$1.86(1.89%)
Day’s Range― - ―
52-Week Range$75.69 - $168.70
Previous CloseN/A
Volume2.14K
Average Volume (3M)2.85K
Market Cap
$61.27B
Enterprise Value$52.34B
Total Cash (Recent Filing)$2.47B
Total Debt (Recent Filing)$2.24B
Price to Earnings (P/E)30.2
Beta0.53
Next Earnings
Jul 23, 2026EPS Estimate
2.62Next Dividend Ex-DateN/A
Dividend Yield0.55%
Share Statistics
EPS (TTM)3.79
Shares Outstanding389,011,320
10 Day Avg. Volume1,843
30 Day Avg. Volume2,850
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.16
Price to Sales (P/S)6.08
P/FCF Ratio25.02
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue6.79
Enterprise Value/Gross Profit9.34
Enterprise Value/Ebitda20.15
Forecast
1Y Price Target
$175.00Price Target Upside10.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)6.25
Revenue Forecast (FY)$9.90B
Bulls Say, Bears Say
Bulls Say
Commercial Execution And Access StrategyManagement's focused launch and access strategy, supported by investments in awareness, diagnosis, and clinician and patient support, aims to expand the treatable hidradenitis suppurativa patient pool and increase prescription volumes.
Pipeline And Label Expansion PotentialPlanned label expansions and a novel pipeline program with a distinct mechanism of action could broaden the addressable market and create additional upside beyond current indications.
Specialist Adoption And Clinical ReputationDermatology specialists regard Bimzelx as a best-in-class option, driving rapid uptake among patients switching from other biologics and those new to biologic therapy.
Bears Say
Investor Sentiment And ExpectationsPersistent investor skepticism about whether HS market expansion will sustain can pressure sentiment and temper expectations for near-term sales and earnings improvement.
Safety And Treatment PersistenceEczema-related side effects are a leading reason for stopping Bimzelx, which could limit treatment continuation and reduce overall patient retention.
Sustainability Of Market GrowthConcerns that hidradenitis suppurativa market growth may decelerate after the initial uptake create uncertainty about the future pace of Bimzelx sales.
UCB SA News
UCBJY FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $75.69 and its highest was $168.70 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $61.27B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 23, 2026 which is in 103 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Feb 26, 2026. The company reported $3.785 earnings per share for the quarter, beating the consensus estimate of $3.16 by $0.625.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Undervalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $0.79 which represents an annual dividend yield of 0.55%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 2.62.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $3.785 in its last earnings report, beating expectations of $3.16. Following the earnings report the stock price went down -7.921%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
UCB SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$175.00 (10.21% Upside)
$175.00 (10.21% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.69%
12-Months-Change
Fundamentals
Return on Equity
15.16%
Trailing 12-Months
Asset Growth
18.72%
Trailing 12-Months
Company Description
UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
UCBJY Company Deck
UCBJY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial story: strong top-line growth, meaningful margin expansion, doubled EPS, sizable commercial traction for BIMZELX and other growth drivers, important regulatory wins (KYGEVVI) and pipeline momentum. Challenges noted include net-price/gross-to-net pressure as access expands, near-term LOE for BRIVIACT, industry headwinds in clinical trials and competitive risks in several programs. On balance the positives (robust growth, profitability, pipeline progress and a strengthened balance sheet) outweigh the challenges, although execution on pricing, trial execution and competitive positioning will be important in 2026.View all UCBJY earnings summariesUCBJY Stock 12 Month Forecast
Average Price Target
$175.00
▲(10.21% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---